{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:12:42Z","timestamp":1794273162082,"version":"4.9.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Roche, Boulogne-Billancourt"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mds177","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T01:57:15Z","timestamp":1341971835000},"page":"2380-2385","source":"Crossref","is-referenced-by-count":52,"title":["Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up"],"prefix":"10.1016","volume":"23","author":[{"given":"P.","family":"Colombat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Brousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Foussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sebban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bergougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lazreg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Solal-Celigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds177_bb0010","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds177_bb0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds177_bb0020","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol."},{"issue":"Suppl 1","key":"10.1093\/annonc\/mds177_bb0025","doi-asserted-by":"crossref","first-page":"i56","DOI":"10.1093\/annonc\/mdi819","article-title":"Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma","volume":"16","author":"Hiddemann","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds177_bb0030","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0040","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0045","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0050","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0055","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds177_bb0060","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/jco.2006.24.18_suppl.7508","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts)","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mds177_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/sonc.2002.30154","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial","volume":"29","author":"Hainsworth","year":"2002","journal-title":"Semin Oncol"},{"issue":"29","key":"10.1093\/annonc\/mds177_bb0075","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1093\/annonc\/mds177_bb0080","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds177_bb0085","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0090","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds177_bb0095","series-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis","author":"Ardeshna","year":"2010"},{"key":"10.1093\/annonc\/mds177_bb0100","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds177_bb0105","first-page":"2432","article-title":"Rituximab activity is potentiated by GM-CSF in patients with relapsed, follicular lymphoma: results of a phase II study","volume":"106","author":"Rossi","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mds177_bb0110","first-page":"4627","article-title":"Comparison of pharmacokinetics and pharmacodynamics of two different dosing regimens of Proleukin(R) (IL-2) in combination with rituximab: The effect of NK cell expansion","volume":"104","author":"Milan","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mds177_bb0115","first-page":"691","article-title":"Active Immunotherapy with FavId(R) (Id\/KLH) following rituximab induction: long-term follow-up of response rate improvement (RRI) and disease progression in follicular lymphoma patients (pts)","volume":"108","author":"Koc","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mds177_bb0120","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","article-title":"Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis","volume":"114","author":"Foran","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds177_bb0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0609.2003.00007.x","article-title":"Loss of CD20 expression in relapsed lymphomas after rituximab therapy","volume":"70","author":"Haidar","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mds177_bb0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1034\/j.1600-0560.2003.00078.x","article-title":"Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy","volume":"30","author":"Clarke","year":"2003","journal-title":"J Cutan Pathol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/9\/2380\/13788747\/mds177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:33:52Z","timestamp":1624440832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419352172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0923753419352172"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds177","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}